Search Results - "Brudi, P."

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials by Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson-Levonas, A. O., Brudi, P.

“…Aim: This post hoc analysis compared the lipid‐altering efficacy and safety of ezetimibe 10 mg plus statin (EZE/statin) vs. statin monotherapy in…”
Get full text

LDL-C treatment gaps in statin-treated patients at high and very high cardiovascular risk in Europe by Gitt, A.K, Ambegaonkar, B, Brudi, P, Lautsch, D

Get full text

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy by Inzucchi, S. E., Tunceli, K., Qiu, Y., Rajpathak, S., Brodovicz, K. G., Engel, S. S., Mavros, P., Radican, L., Brudi, P., Li, Z., Fan, C. P. S., Hanna, B., Tang, J., Blonde, L.

“…Aim To assess time to insulin initiation among patients with type 2 diabetes mellitus (T2DM) treated with sitagliptin versus sulphonylurea as add‐on to…”
Get full text

Statin treated patients at very high cardiovascular risk in Europe: Are the majority close to LDL-C by Lautsch, D, Gitt, A.K, Brudi, P, Vanneste, B, Ambegaonkar, B

Get full text

Low LDL-C target achievement among treated acs patients in germany: the dyslipidemia international study (dysis) iiacs results by Gitt, A, Ashton, V, Horack, M, Jannowitz, C, Brudi, P, Lautsch, D, Ambegaonkar, B

Get full text

Prevalence of lipid abnormalities among treated ACS patients in Greece: The Dyslipidemia International Study (DYSIS) II ACS results by Pitsavos, C, Alexopoulos, D, Goudevenos, J, Xixi, E, Gitt, A, Horack, M, Ashton, V, Brudi, P, Lautsch, D, Ambegaonkar, B

Get full text

Lipid abnormalities remain high among diabetic patients with stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium by Hermans, M, Cools, F, Gevaert, S, Missault, L, Gitt, A, Horack, M, Ashton, V, Brudi, P, Lautsch, D, Ambegaonkar, B

Get full text

LDL-C target attainment among treated ACS patients in Hong Kong and Taiwan: The Dyslipidemia International Study (DYSIS) II ACS results by Yan, B.P, Chiang, F.T, Gitt, A, Horack, M, Ashton, V, Brudi, P, Balaji, H.P, Ambegaonkar, B

Get full text

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study by Farnier, M, Averna, M, Missault, L, Vaverkova, H, Viigimaa, M, Massaad, R, Vandormael, K, Johnson-Levonas, A O, Brudi, P

“…To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg vs. rosuvastatin (ROSUVA) 10 mg. In this…”
Get more information

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome by Jimenez, J. G., Rosen, J. B., Pirags, V., Massaad, R., Hanson, M. E., Brudi, P., Triscari, J.

“…Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to…”
Get full text

PO368 DISCONTINUATION AND ADHERENCE FOR SITAGLIPTIN VERSUS SULFONYLUREA AS ADD-ON TO METFORMIN by Tunceli, K, Zhao, C.G, Brodovicz, K, Mavros, P, Engel, S, Radican, L, Rajpathak, S, Qiu, Y, Brudi, P, Yong, C, Bloomgarden, Z, Fonseca, V

Get full text

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study by Reckless, J P D, Henry, P, Pomykaj, T, Lim, S T, Massaad, R, Vandormael, K, Johnson-Levonas, A O, Lis, K, Brudi, P, Allen, C

“…The aim of this study was to investigate the efficacy and safety profile of switching to ezetimibe/simvastatin (Eze/Simva) 10/40 mg compared with doubling the…”
Get more information

Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event by Brudi, P, Reckless, J P, Henry, D P, Pomykaj, T, Lim, S T, Massaad, R, Vandormael, K, Johnson-Levonas, A O

“…The aim of the study was to compare the efficacy/safety of doubling the dose of low-, medium- and high-potency statins on lipids/lipoproteins versus…”
Get more information

P236 Corrélations entre les taux de LDL-cholestérol, non HDL-cholestérol et apolipoprotéine B dans les dyslipidémies mixtes et influence de divers traitements hypolipémiants by Farnier, M, Hannachi, H, Dong, Q, Shah, A, Brudi, P

“…Introduction Il a été montré qu’un traitement par statine modifie les corrélations entre les taux de LDL-cholestérol (LDL-C), non HDL-cholestérol (non HDL-C)…”
Get full text

Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (The SILVER trial) by COHEN, A, BREGMAN, B, AGABITI ROSEI, E, WILLIAMS, B, DUBOURG, O, CLAIREFOND, P, BRUDI, P, GOSSE, P, GUERET, P

“…The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II…”
Get full text

Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II by Poh, Kian-Keong, Chin, Chee Tang, Tong, Khim Leng, Tan, Julian Ko Beng, Lim, Jee Seong, Yu, Weixuan, Horack, Martin, Vyas, Ami, Lautsch, Dominik, Ambegaonkar, Baishali, Brudi, Philippe, Gitt, Anselm K

“…Dyslipidaemia is a major risk factor for coronary heart disease (CHD). There is a lack of data on the extent of lipid abnormalities and lipid-lowering therapy…”
Get full text

Improvement in achievement of lipid targets in France: comparison of data from the DYSIS I and DYSIS II studies by Ferrières, J., Velkovski Rouyer, M., Lautsch, D., Ashton, V., Ambegaonkar, B.M., Brudi, P., Gitt, A.K.

Get full text

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study by Azar, Sami T, Hantash, Hadi Abu, Jambart, Selim, El-Zaheri, Mohamed M, Rachoin, Rachoin, Chalfoun, Amal, Lahoud, Layla, Okkeh, Osama, Bramlage, Peter, Brudi, Philippe, Ambegaonkar, Baishali M

“…Cardiovascular disease is the leading cause of death and disability worldwide. Therefore, as part of the Dyslipidemia International Study (DYSIS), we have…”
Get full text

Use of guideline-recommended treatments in 10,661 patients with coronary heart disease: Observational multinational DYSIS II study by Ferrieres, J., Lautsch, D., Velkovski-Rouyer, M., Ambegaonkar, B., De Ferrari, G., Vyas, A., Baxter, C., Horack, M., Bash, L., Al Mahmeed, W., Chiang, F.T., Keong Poh, K., Brudi, P., Gitt, A.

Get full text

PCV93 COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED WITH DOUBLING THE STATIN DOSE: ANALYSIS OF THE INFORCE STUDY IN THE UK by Reckless, JP, Davies, GM, Tunceli, K, Hu, XH, Brudi, P

Get full text